Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01.-MedSci.cn

Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01.

Smit, EF; Nakagawa, K; Nagasaka, M; Felip, E; Goto, Y; Li, BT; Pacheco, JM; Murakami, H; Barlesi, F; Saltos, AN; Perol, M; Udagawa, H; Saxena, K; Shiga, R; Guevara, FM; Acharyya, S; Shahidi, J; Planchard, D; Janne, PA

JOURNAL OF CLINICAL ONCOLOGY, 2020; 38 (15):

科室
- - 订阅+
  - 更多科室
工具
服务